Abstract
Excitatory neurotransmission mediated by NMDA (N-methyl-D-aspartic acid) receptors plays a key role in both healthy and diseased processes in the brain. Therefore, bioactive compounds that can interact selectively with these receptors have been the aim of extensive research in the search of effective therapeutic agents or, at least, useful pharmacological tools. NMDA receptors are heteromeric ion channels that contain different modulatory sites capable to bind subunit-selective ligands. In particular, the activation of NMDA receptors requires two distinct ligands: glutamate (the endogenous agonist) and glycine (the co-agonist). In view of the renewed interest in this research area and the high therapeutic potential of this target, this review presents an updated survey of ligands which interact with the glutamate binding-site of the NMDA receptors, their rational development, and data on the structure-activity relationship which are of utmost importance for the design of novel lead compounds.
Keywords: Glutamate, NMDA receptors, competitive agonists, competitive antagonists, neurotransmission, (N-methyl-D-aspartic acid), pharmacological, endogenous, neuropathological, tetrameric
Current Medicinal Chemistry
Title: Glutamate Binding-Site Ligands of NMDA Receptors
Volume: 18 Issue: 36
Author(s): C. Bonaccorso, N. Micale, R. Ettari, S. Grasso and M. Zappala
Affiliation:
Keywords: Glutamate, NMDA receptors, competitive agonists, competitive antagonists, neurotransmission, (N-methyl-D-aspartic acid), pharmacological, endogenous, neuropathological, tetrameric
Abstract: Excitatory neurotransmission mediated by NMDA (N-methyl-D-aspartic acid) receptors plays a key role in both healthy and diseased processes in the brain. Therefore, bioactive compounds that can interact selectively with these receptors have been the aim of extensive research in the search of effective therapeutic agents or, at least, useful pharmacological tools. NMDA receptors are heteromeric ion channels that contain different modulatory sites capable to bind subunit-selective ligands. In particular, the activation of NMDA receptors requires two distinct ligands: glutamate (the endogenous agonist) and glycine (the co-agonist). In view of the renewed interest in this research area and the high therapeutic potential of this target, this review presents an updated survey of ligands which interact with the glutamate binding-site of the NMDA receptors, their rational development, and data on the structure-activity relationship which are of utmost importance for the design of novel lead compounds.
Export Options
About this article
Cite this article as:
Bonaccorso C., Micale N., Ettari R., Grasso S. and Zappala M., Glutamate Binding-Site Ligands of NMDA Receptors, Current Medicinal Chemistry 2011; 18 (36) . https://dx.doi.org/10.2174/092986711798347225
DOI https://dx.doi.org/10.2174/092986711798347225 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Proteomics Annotation of Lipid Rafts Modified by Virus Infection
Combinatorial Chemistry & High Throughput Screening Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Tissue Distribution of Glutamate Carboxypeptidase II (GCPII) with a Focus on the Central and Peripheral Nervous System
Current Medicinal Chemistry Editorial (Thematic Selection: Strategies of Current Drugs and Alternative Treatments for Neurodegenerative Diseases)
Current Neuropharmacology Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Current Development in Encapsulated Cell Therapy for Degenerative Retinopathies
Current Tissue Engineering (Discontinued) Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets A Neurotrophic Rationale for the Therapy of Neurodegenerative Disorders
Current Alzheimer Research Autophagy Modulators and Neuroinflammation
Current Medicinal Chemistry Resolvins: Endogenously-Generated Potent Painkilling Substances and their Therapeutic Perspectives
Current Neuropharmacology Selenium and Clinical Trials: New Therapeutic Evidence for Multiple Diseases
Current Medicinal Chemistry Topiramate: Its Pharmacological Properties and Therapeutic Efficacy in Epilepsy
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member:
Current Alzheimer Research Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Amyloid-Related Biomarkers for Alzheimers Disease
Current Medicinal Chemistry Mast Cell – Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications
CNS & Neurological Disorders - Drug Targets Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry